BOPA Collaboration Webinar – Highlights from COSA ASM 2024

Wednesday 26th February 2025 at 21:00 GMT

(27th Feb 07:00 ASET or 26th Feb 14:00 Canadian MST)

Click HERE to register

(For COSA CPG members click here, CAPhO members click here)

The BOPA Education and Training Subcommittee would like to invite you to the international collaboration webinar series with Clinical Oncology Society of Australia – Clinical Pharmacists Group (COSA CPG) and Canadian Association of Pharmacy in Oncology (CAPhO).

We have invited the following speakers to present the COSA ASM Highlights 2024.

  • Bishma Jayathilaka from Peter Mac (tied winner for Best of the Best Oral presentation on Clinical Research) – Estimating rates of immune-related adverse events in an Australian state-wide hospital population
  • Lachlan Roth from The Princess Alexandra Hospital – Cytokine release syndrome incidence with tebentafusp: A case series of real-world data at two hospitals 
  • Madeleine Washbourne from The Princess Alexandra Hospital – Dapsone dosing for PJP prophylaxis: Breaking down guidelines and building safer alternatives

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article